Overview

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis) tablets coadministered to healthy participants in the fasted and fed states.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Metformin
Saxagliptin